Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Fuji
Queensland Health
Teva
Farmers Insurance
Julphar
Cerilliant
Colorcon
US Army

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,062,667

« Back to Dashboard

Summary for Patent: 8,062,667
Title:Modified release formulations containing drug-ion exchange resin complexes
Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
Inventor(s): Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee: Tris Pharma, Inc. (Monmouth Junction, NJ)
Application Number:11/724,966
Patent Claim Types:
see list of patent claims
Composition; Process; Formulation;

Drugs Protected by US Patent 8,062,667

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Nextwave Pharms QUILLIVANT XR methylphenidate hydrochloride FOR SUSPENSION, EXTENDED RELEASE;ORAL 202100-001 Sep 27, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Tris Pharma Inc KARBINAL ER carbinoxamine maleate SUSPENSION, EXTENDED RELEASE;ORAL 022556-001 Mar 28, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Vernalis R And D Ltd TUZISTRA XR chlorpheniramine polistirex; codeine polistirex SUSPENSION, EXTENDED RELEASE;ORAL 207768-001 Apr 30, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,062,667

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,675,704 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,549,989 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,202,537 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,883,217 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,747,902 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,522,191 Modified release formulations containing drug--ion exchange resin complexes ➤ Subscribe
8,790,700 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,337,890 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,491,935 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,597,684 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,062,667

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 536867 ➤ Subscribe
Australia 2007227569 ➤ Subscribe
Brazil PI0709606 ➤ Subscribe
Canada 2645855 ➤ Subscribe
China 101400343 ➤ Subscribe
China 102488652 ➤ Subscribe
Denmark 2018160 ➤ Subscribe
Denmark 2428205 ➤ Subscribe
European Patent Office 2018160 ➤ Subscribe
European Patent Office 2428205 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Accenture
Dow
Express Scripts
Julphar
Fuji
Farmers Insurance
Mallinckrodt
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot